Fulcrum Therapeutics(FULC)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

FULC Fulcrum Therapeutics

盘前交易 11-19 07:21:13 EST

3.03

+0.03

+0.83%

最高3.10	最低2.93	成交量235.52万
今开3.01	昨收3.01	日振幅5.66%
总市值1.63亿	流通市值9,691万	总股本5,394万
成交额711.31万	换手率7.36%	流通股本3,198万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"FULC","market":"US","secType":"STK","nameCN":"Fulcrum Therapeutics","latestPrice":3.03,"timestamp":1731963600000,"preClose":3.005,"halted":0,"volume":2355184,"delay":0,"floatShares":31984600,"shares":53938661,"eps":-0.288364,"marketStatus":"盘前交易","marketStatusCode":1,"change":0.025,"latestTime":"11-19 07:21:13 EST","open":3.01,"high":3.1,"low":2.93,"amount":7113143.203088,"amplitude":0.056572,"askPrice":3.63,"askSize":100,"bidPrice":2.72,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.288364,"exchange":"NASDAQ","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732026600000},"adr":0,"listingDate":1563422400000,"adjPreClose":3.03,"postHourTrading":{"tag":"盘后","latestPrice":3.03,"preClose":3.03,"latestTime":"19:47 EST","volume":10786,"amount":32682.58,"timestamp":1731977242086},"volumeRatio":2.718175529462148,"impliedVol":0.9053,"impliedVolPercentile":0.5498},"requestUrl":"/m/hq/s/FULC","defaultTab":"news","newsList":[{"id":"2483588053","title":"Fulcrum Therapeutics Inc 报告本季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2483588053","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483588053?lang=zh_cn&edition=full","pubTime":"2024-11-13 23:26","pubTimestamp":1731511562,"startTime":"0","endTime":"0","summary":"Fulcrum Therapeutics Inc 报告本季度业绩 - 收益摘要Fulcrum Therapeutics Inc FULC.OQ报告本季度调整后每股亏损35美分，高于去年同期的每股-39美分。报告收入为零，分析师预期为零。Fulcrum Therapeutics Inc 报告的季度每股收益为亏损 35 美分。该公司当季亏损 2170 万美元。Fulcrum Therapeutics Inc 本季度股价上涨了 2.0%，今年迄今为止亏损了 46.1%。华尔街对 Fulcrum Therapeutics Inc 的 12 个月目标价中位数为 4.00 美元。如有任何其他问题或反馈，请联系 RefinitivNewsSupport@thomsonreuters.com。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nL4S3MK1MM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FULC","BK4007"],"gpt_icon":0},{"id":"2482739486","title":"Fulcrum Therapeutics Inc 预计每股亏损41美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2482739486","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482739486?lang=zh_cn&edition=full","pubTime":"2024-11-11 23:38","pubTimestamp":1731339518,"startTime":"0","endTime":"0","summary":"Fulcrum Therapeutics Inc 预计每股亏损41美分 - 财报前瞻Fulcrum Therapeutics Inc FULC.OQ FULC.O将于11月13日公布截至2024年9月30日的财报，预计该公司的季度收入将出现下降。LSEG分析师对Fulcrum Therapeutics Inc的平均预期是每股亏损41美分。华尔街对 Fulcrum Therapeutics Inc 的 12 个月目标价中位数为 4.00 美元，高于其上次收盘价 3.49 美元。11月11日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。如有任何其他问题或反馈，请联系 RefinitivNewsSupport@thomsonreuters.com。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241111:nL4S3MI15T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FULC"],"gpt_icon":0},{"id":"2481013184","title":"Fulcrum Therapeutics, Inc.盘中异动 大幅拉升5.54%报3.62美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481013184","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481013184?lang=zh_cn&edition=full","pubTime":"2024-11-08 01:46","pubTimestamp":1731001561,"startTime":"0","endTime":"0","summary":"北京时间2024年11月08日01时46分，Fulcrum Therapeutics, Inc.股票出现异动，股价急速拉升5.54%。截至发稿，该股报3.62美元/股，成交量44.8657万股，换手率0.72%，振幅5.98%。Fulcrum Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.98%。其相关个股中，Celularity Inc C/Wts 16/07/2026 、Celularity Inc.、Ensysce Biosciences, Inc.涨幅较大，Ensysce Biosciences, Inc.、Elevai Labs, Inc.、Cyclacel Pharmaceuticals, Inc.较为活跃，换手率分别为904.92%、436.68%、115.97%，振幅较大的相关个股有Celularity Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、180 Life Sciences Corp C/Wts 07/11/2025，振幅分别为84.83%、72.18%、68.89%。Fulcrum Therapeutics, Inc.公司简介：Fulcrum Therapeutics Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110801460195bde879&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110801460195bde879&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","BK4007","FULC"],"gpt_icon":0},{"id":"2481532257","title":"Fulcrum Therapeutics, Inc.盘中异动 大幅上涨5.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2481532257","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481532257?lang=zh_cn&edition=full","pubTime":"2024-11-05 01:50","pubTimestamp":1730742636,"startTime":"0","endTime":"0","summary":"北京时间2024年11月05日01时50分，Fulcrum Therapeutics, Inc.股票出现波动，股价快速上涨5.30%。截至发稿，该股报3.38美元/股，成交量51.8753万股，换手率0.83%，振幅7.17%。Fulcrum Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.03%。其相关个股中，Neurogene Inc.、Tenaya Therapeutics, Inc.、Disc Medicine, Inc.涨幅较大，Elevai Labs, Inc.、Nls Pharmaceutics Ltd.、Gri Bio, Inc.较为活跃，换手率分别为384.94%、277.29%、79.95%，振幅较大的相关个股有Sab Biotherapeutics Inc C/Wts 22/10/2026 、In8Bio, Inc.、Neurogene Inc.，振幅分别为52.25%、45.39%、39.98%。Fulcrum Therapeutics, Inc.公司简介：Fulcrum Therapeutics Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241105015036ab9f119a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241105015036ab9f119a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","FULC","LENZ","BK4007"],"gpt_icon":0},{"id":"2477453418","title":"Fulcrum Therapeutics, Inc.盘中异动 早盘股价大跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2477453418","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477453418?lang=zh_cn&edition=full","pubTime":"2024-10-23 22:52","pubTimestamp":1729695120,"startTime":"0","endTime":"0","summary":"北京时间2024年10月23日22时52分，Fulcrum Therapeutics, Inc.股票出现异动，股价大幅下挫5.01%。Fulcrum Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.03%。其相关个股中，Cns Pharmaceuticals, Inc.、Virax Biolabs Group Limited、Tevogen Bio Holdings Inc.涨幅较大，Virax Biolabs Group Limited、Cns Pharmaceuticals, Inc.、Cyclacel Pharmaceuticals, Inc.较为活跃，换手率分别为1671.97%、1129.27%、367.19%，振幅较大的相关个股有Cns Pharmaceuticals, Inc.、Tevogen Bio Holdings Inc.、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 ，振幅分别为71.86%、68.32%、64.81%。Fulcrum Therapeutics, Inc.公司简介：Fulcrum Therapeutics Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241023225200a1e42bef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241023225200a1e42bef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","FULC","LENZ"],"gpt_icon":0},{"id":"2474237567","title":"Fulcrum Therapeutics, Inc.盘中异动 临近午盘大幅下跌5.28%报3.23美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2474237567","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474237567?lang=zh_cn&edition=full","pubTime":"2024-10-10 23:39","pubTimestamp":1728574771,"startTime":"0","endTime":"0","summary":"北京时间2024年10月10日23时39分，Fulcrum Therapeutics, Inc.股票出现异动，股价急速跳水5.28%。Fulcrum Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.34%。其相关个股中，Nls Pharmaceutics Ltd C/Wts 02/02/2026、Pasithea Therapeutics Corp C/Wts 12/08/2026 、Tc Biopharm  Plc C/Wts 10/02/2028 涨幅较大，Aditxt, Inc.、Tempest Therapeutics, Inc.、Clearmind Medicine Inc.较为活跃，换手率分别为298.73%、172.47%、109.40%，振幅较大的相关个股有Nls Pharmaceutics Ltd C/Wts 02/02/2026、Seastar Medical Holding Corp C/Wts 28/10/2027 、Pasithea Therapeutics Corp C/Wts 12/08/2026 ，振幅分别为106.67%、66.67%、49.35%。Fulcrum Therapeutics, Inc.公司简介：Fulcrum Therapeutics Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410102339319719f8d1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410102339319719f8d1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["FULC","BK4007","LENZ","BK4139"],"gpt_icon":0},{"id":"2472748330","title":"Fulcrum Therapeutics, Inc.盘中异动 股价大跌5.01%报3.58美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2472748330","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2472748330?lang=zh_cn&edition=full","pubTime":"2024-10-01 02:23","pubTimestamp":1727720601,"startTime":"0","endTime":"0","summary":"北京时间2024年10月01日02时23分，Fulcrum Therapeutics, Inc.股票出现异动，股价急速跳水5.01%。截至发稿，该股报3.58美元/股，成交量44.1164万股，换手率0.71%，振幅6.37%。Fulcrum Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.57%。Fulcrum Therapeutics, Inc.公司简介：Fulcrum Therapeutics Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241001022321ab67310c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241001022321ab67310c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","FULC","LENZ","BK4139"],"gpt_icon":0},{"id":"2470086175","title":"Fulcrum Therapeutics, Inc.盘中异动 早盘急速上涨5.70%","url":"https://stock-news.laohu8.com/highlight/detail?id=2470086175","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470086175?lang=zh_cn&edition=full","pubTime":"2024-09-27 21:31","pubTimestamp":1727443874,"startTime":"0","endTime":"0","summary":"北京时间2024年09月27日21时31分，Fulcrum Therapeutics, Inc.股票出现异动，股价快速拉升5.70%。截至发稿，该股报4.23美元/股，成交量5.4262万股，换手率0.09%，振幅2.50%。Fulcrum Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.58%。其相关个股中，Pasithea Therapeutics Corp C/Wts 12/08/2026 、Onconetix, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大，Onconetix, Inc.、Cardio Diagnostics Holdings Inc.、Seelos Therapeutics, Inc.较为活跃，换手率分别为1852.79%、60.86%、44.67%，振幅较大的相关个股有Biomea Fusion, Inc.、Traws Pharma, Inc.、Tonix Pharmaceuticals Holding Corp.，振幅分别为8.98%、8.81%、8.64%。Fulcrum Therapeutics, Inc.公司简介：Fulcrum Therapeutics Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240927213114a1dd108c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240927213114a1dd108c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","FULC","LENZ"],"gpt_icon":0},{"id":"2470517007","title":"BUZZ--美国股票走势-Crocs、First Solar、高通公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2470517007","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470517007?lang=zh_cn&edition=full","pubTime":"2024-09-27 00:14","pubTimestamp":1727367247,"startTime":"0","endTime":"0","summary":"        *      Eikon 个股走势搜索字符串：[STXBZ］        *      The Day Ahead 新闻通讯：          *      The Morning News Call时事通讯：      9月26日 - 华尔街主要股指周四上涨，标普500指数创下历史新高，原因是美光公司的乐观预测重燃了人工智能热潮，而一份申请失业救济人数低于预期的报告舒缓了人们对劳动力市场的担忧。美东时间11:38，道琼斯工业平均指数  上涨0.5%，至42135.45点。标普500指数  上涨0.22%，报5,734.93 点；纳斯达克综合指数  上涨0.23%，报18,124.285点。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"19d76ac8a99e856ca115d767258d984a","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNX","CDE","EOG","CVX","FULC","SNX","SHOT","TQQQ","COP","L","JEF","HAL","LNG","UAA",".IXIC","2NVD.UK","UDOW","SONO","WVE","QCOM","DJX","FANG","AGIO","3NVD.UK",".DJI","TLN","MRVL","DDM","KMX","CROX","WMB","XOM","NQmain","RRC","DOG","CLNE",".SPX"],"gpt_icon":1},{"id":"2470075677","title":"分析师称，辉瑞退出 Oxbryta 可能会加速竞争对手试验性镰状细胞药物的试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2470075677","media":"Reuters","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470075677?lang=zh_cn&edition=full","pubTime":"2024-09-26 23:36","pubTimestamp":1727364983,"startTime":"0","endTime":"0","summary":"Oxbryta是至少六种镰状细胞病治疗药物之一，主要用于轻度至中度症状的患者。至少有三家华尔街券商表示，撤销授权可能会导致立即加快对竞争对手的治疗遗传性疾病的药物进行试验，包括Agios Pharmaceuticals公司的   mitapivat和Fulcrum Therapeutics公司的   pociredir。Stifel 公司分析师 Dae Gon Ha 周四表示，Oxbryta 的停产可能会使绝大多数轻中度患者依赖化疗药物羟基脲。据辉瑞公司网站介绍，该公司还收购了另外两种试验性镰状细胞疗法，这两种疗法目前仍在临床试验中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"31475a2f05bb5a0cf2e7acfeae2c0e13","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFE","SGXZ57979304.SGD","IE00B19Z3B42.SGD","LU0320765992.SGD","LU2362540622.SGD","SG9999001176.USD","SG9999013999.USD","IE00BLSP4452.SGD","LU0225771236.USD","LU0234570918.USD","LU2236285917.USD","LU1585245621.USD","IE00BBT3K403.USD","LU0321505868.SGD","LU2417539215.USD","LU0321505439.SGD","IE00BJT1NW94.SGD","LU0417517546.SGD","PIPR","BK4533","LU1035775433.USD","IE00BLSP4239.USD","BK4007","FULC","LU0256863811.USD","LU0122379950.USD","BK4127","SG9999001176.SGD","LU0058720904.USD","LU1023059063.AUD","BK4532","LU0061475181.USD","LU0234572021.USD","LU0868494617.USD","BK4550","LU0289739699.SGD","LU1093756168.USD","IE00B894F039.SGD","IE00BJJMRZ35.SGD","IE0002270589.USD","LU2237438978.USD","LU1894683348.USD","IE00B19Z9P08.USD","BK4567","BK4534","LU1066051498.USD","VRTX","IE000M9KFDE8.USD","LU1057294990.SGD","IE00B19Z9Z06.USD"],"gpt_icon":1},{"id":"2470573006","title":"BUZZ-辉瑞撤出镰状细胞药物后，镰状细胞药物开发商数量增加","url":"https://stock-news.laohu8.com/highlight/detail?id=2470573006","media":"Reuters","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470573006?lang=zh_cn&edition=full","pubTime":"2024-09-26 22:36","pubTimestamp":1727361370,"startTime":"0","endTime":"0","summary":"    9月26日 - ** Agios Pharmaceuticals   股价上涨~3%，报50.29美元；Fulcrum Therapeutics   上涨~20%，报4.15美元 ** 较大的竞争对手辉瑞  从所有获批市场撤出其镰状细胞病药物Oxbryta， ，理由是该药物有引发痛苦的并发症和死亡的风险。** 镰状细胞病是一种遗传性血液疾病，会影响红细胞中的血红蛋白** 分析师预计，该药的退出将有助于促进竞争对手镰状细胞病药物的试验注册。** Leerink Partners的分析师称，Oxbryta的退出可能会对FULC早期研究的入组产生积极影响，尤其是正在或曾经单独服用Oxbryta的患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"31475a2f05bb5a0cf2e7acfeae2c0e13","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1057294990.SGD","BK4533","LU0122379950.USD","BK4592","AGIO","LU1883839398.USD","SG9999001176.USD","BK4588","IE0002270589.USD","IE00B19Z3581.USD","SG9999013999.USD","SG9999003800.SGD","IE000M9KFDE8.USD","BK4585","LU0170899867.USD","IE00BLSP4239.USD","BK4550","LU0456855351.SGD","SG9999002224.SGD","SG9999002232.USD","LU0225284248.USD","LU0321505439.SGD","LU0225771236.USD","LU0321505868.SGD","BK4534","IE00BLSP4452.SGD","BK4007","BK4568","SG9999001176.SGD","SGXZ57979304.SGD","LU1894683348.USD","FULC","LU1023059063.AUD","BK4581","IE00BBT3K403.USD","LU0868494617.USD","LU1066051498.USD","LU1066053197.SGD","LU0306807586.USD","PFE","IE00B19Z3B42.SGD","LU1894683264.USD","LU0306806265.USD","LU0985481810.HKD","LU0234572021.USD","BK4139","LU0289739699.SGD","SG9999011175.SGD","LU0058720904.USD"],"gpt_icon":1},{"id":"2467714846","title":"美国研究综述-星座能源公司、礼来公司、塔伦能源公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2467714846","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467714846?lang=zh_cn&edition=full","pubTime":"2024-09-13 15:51","pubTimestamp":1726213914,"startTime":"0","endTime":"0","summary":"    路透9月13日 - 周五，华尔街证券分析师修改了对几家美国上市公司的评级和目标价，其中包括星座能源公司、礼来公司和泰伦能源公司。* Fulcrum Therapeutics Inc   ：加拿大皇家银行将目标价从15美元下调至4美元 * Fulcrum Therapeutics Inc   ：加拿大皇家银行将其评级从 \"跑赢大盘 \"下调至 \"行业表现\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0234572021.USD","PLAY","ORKA","LU0965509101.SGD","CEG","IE00BMG7P587.USD","IE00BLSP4239.USD","IE00BLSP4452.SGD","FERG","HAL","RH","TLN","JNJ","ALK","BK4216","EW","VST","TTD","LU0130102774.USD","FULC","LU1267930813.SGD","GEV","CPB","KIDS","PEG","VRDN","LU0417517546.SGD","BK4212","NRG","BK4581","DOW","LU1244550577.SGD","IE00BD4GTT62.SGD","SHLS","LU1165135440.EUR","BK4592","AVTR","KR","WDC","LU2298322129.HKD","LLY","MODV","ZBH","IBEX","USB","BK4105","LH"],"gpt_icon":1},{"id":"1179497928","title":"Fulcrum Therapeutics洛司马匹德三期临床试验失利，股价重挫逾60%","url":"https://stock-news.laohu8.com/highlight/detail?id=1179497928","media":"华尔街洞察","labels":["analysis"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179497928?lang=zh_cn&edition=full","pubTime":"2024-09-13 08:20","pubTimestamp":1726186800,"startTime":"0","endTime":"0","summary":"纳斯达克上市公司$Fulcrum Therapeutics$, Inc.今日股价暴跌超过60%,主要原因是其主导候选药物洛司马匹德未能在治疗肌肉营养不良症的关键三期临床试验REACH中达到预期目标。根据Fulcrum发布的声明,REACH试验未能达到评估肌肉力量恢复的主要终点指标,次要终点指标也未达到显著性水平。Fulcrum CEO Alex C. Sapir表示,鉴于这些不利结果,公司将暂停洛司马匹德在FSHD适应证的进一步开发。这对Fulcrum无疑是一个重大打击。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MFI","BK4550","IE00B7SZLL34.SGD","LU2462157665.USD","SGXZ57979304.SGD","VRTX","PRO","LU1093756325.SGD","LU1201861165.SGD","BK1583","RHHBY","SCD","LU2456880835.USD","03347","FULC","LU0234570918.USD","LU2237443978.SGD","PFE","SNY","LU2237443622.USD","LU1366192091.USD","IE00BKVL7J92.USD","LU0170899867.USD","BLUE","BK1141","BK4505","BK4552","BK4556","IE00B2B36J28.USD","LU1093756168.USD","LU0648001328.SGD","LU2237443549.SGD","LU1718418525.SGD","BAC","RNA","BK4207","IE00BJJMRZ35.SGD","BK4139","BK4581","LU1883839398.USD","LU0070302665.USD","LU0889565916.HKD","BK4127","BK4568","LENZ","LU2237443465.HKD","LU1861558580.USD","CRSP","IE00BFTCPJ56.SGD","LU0079474960.USD","LU0130102774.USD","BK1576","BK4007","LU1066053197.SGD","LU1668664300.SGD","LU0208291251.USD","03165"],"gpt_icon":0},{"id":"2467200010","title":"BUZZ--美国股票走势-金矿矿工、银矿矿工、华纳兄弟发现公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2467200010","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467200010?lang=zh_cn&edition=full","pubTime":"2024-09-13 00:02","pubTimestamp":1726156935,"startTime":"0","endTime":"0","summary":"        *      个股走势的 Eikon 搜索字符串：[STXBZ］        *      The Day Ahead 新闻通讯：          *      The Morning News Call时事通讯：      9月12日 - 周四，华尔街股市变化不大，此前火热的生产者物价数据使得美联储小幅降息25个基点的可能性依然存在，而疫苗生产商莫德纳的股价则在不乐观的收入预期之后出现下滑。美东时间11:42，道琼斯工业平均指数  持平于40,842.63点。标普500指数  上涨0.11%，报5560.17点；纳斯达克综合指数  上涨0.34%，报17455.082点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCT","CDE","AURA",".DJI","NEM","LU1023059493.AUD","DDM","NTGR","HL","MPW","DBI","GILD","MNQmain","PSQ","DAL","KR","WMG","QLD","NQmain","COIN","MRNA","SDOW","ELF","QID","VNOM","WBD","DOG",".SPX","GEV","ALK","CURV","IPG","SQQQ","USB","DJX","OXM","RYDE","RH","BK4570","LOVE","UDOW","FULC","TQQQ","DXD","VRDN","GEVO","BK4585",".IXIC","DOW","SIG"],"gpt_icon":1},{"id":"2466427074","title":"BUZZ--美国股票走势-Fulcrum Therapeutics、Summit Therapeutics、Signet Jewelers","url":"https://stock-news.laohu8.com/highlight/detail?id=2466427074","media":"Reuters","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466427074?lang=zh_cn&edition=full","pubTime":"2024-09-12 21:19","pubTimestamp":1726147150,"startTime":"0","endTime":"0","summary":"        *      个股走势的 Eikon 搜索字符串：[STXBZ］        *      The Day Ahead 新闻通讯：          *      The Morning News Call时事通讯：      9月12日 - 在美联储下周可能降息之前，华尔街期货周四在即将公布经济数据之前走高。美东时间9:08，道指电子盘  上涨0.10%，报40945点。标普500指数小型股  上涨0.12%，报收于5,568点；纳斯达克100指数小型股  上涨0.01%，报收于19,273.5点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CURV","VRDN","LU1242518857.USD","BK4007","BK4213","AURA","LU0170899867.USD","BK4095","LU2237438978.USD","USB","BK4504","IE00BFXG1179.USD","BK4207","BK4139","SIG","BK4500","BK4548","LOVE","BK4225","ELF","BK4008","LU0566484027.USD","LU2488822045.USD","LU0053671581.USD","SMMT","BK4532","BK4559","BK4090","MPW","LU0979878070.USD","BK4534","BK4568","FULC","BK4551","BK4501","BK4183","BK4094","LU1559883803.SGD","ALK","BK4585","BK4588","LU1242518931.SGD","BK4200","BK4539","VNOM","DOW","BK4533","BK4203","LENZ"],"gpt_icon":1},{"id":"2466276769","title":"BUZZ-Fulcrum Therapeutics 因肌肉失调药物在后期研究中失败而受挫","url":"https://stock-news.laohu8.com/highlight/detail?id=2466276769","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466276769?lang=zh_cn&edition=full","pubTime":"2024-09-12 19:54","pubTimestamp":1726142090,"startTime":"0","endTime":"0","summary":"    9月12日 - ** 药物开发商Fulcrum Therapeutics   股价盘前暴跌70.62%，至2.60美元** 该公司称， ，其治疗遗传性肌肉疾病的实验药物在一项后期研究中未能达到主要目标** 该公司正在对其口服药物losmapimod进行测试，测试对象是260名面岬肱肌营养不良症患者，这些患者在48周的时间里要么接受该疗法，要么接受安慰剂治疗。** Adds 将暂停未来 losmapimod 的开发** FSHD是一种罕见的遗传性肌肉疾病，脸部、肩胛骨和上臂肌肉受影响最大** 截至上一交易日收盘，股价年累计上涨约 31","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FULC","BK4007","BK4139","LENZ"],"gpt_icon":0},{"id":"2466275979","title":"更新版 1-肌肉失调药物在后期研究中失败，Fulcrum 股票暴跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2466275979","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466275979?lang=zh_cn&edition=full","pubTime":"2024-09-12 19:34","pubTimestamp":1726140852,"startTime":"0","endTime":"0","summary":"     路透9月12日 - Fulcrum Therapeutics   周四表示，其治疗一种肌肉疾病的实验性药物未能在一项后期研究中达到主要目标，导致该公司股价在收盘前下跌近70%。该公司正在对其药物losmapimod进行测试，260名面胛肱肌营养不良症患者 接受了48周的治疗或安慰剂治疗。鉴于上述结果，该公司表示计划暂停losmapimod在FSHD患者中的试验。FSHD是一种遗传性疾病，会导致面部、肩胛骨和上臂肌肉无力和萎缩。据肌肉萎缩症协会估计，该病的发病率约为每10万人中有4例。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","FULC"],"gpt_icon":0},{"id":"2466278798","title":"Fulcrum 的肌肉失调药物在后期研究中失败","url":"https://stock-news.laohu8.com/highlight/detail?id=2466278798","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466278798?lang=zh_cn&edition=full","pubTime":"2024-09-12 19:08","pubTimestamp":1726139297,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透9月12日 - Fulcrum Therapeutics   周四称，该公司用于治疗一种遗传性肌肉疾病的实验性药物未能在一项后期研究中达到主要目标。在盘前交易中，该公司股价下跌超过70%，至2.4美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","FULC"],"gpt_icon":0},{"id":"2459206894","title":"Fulcrum Therapeutics, Inc.盘中异动 股价大涨5.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2459206894","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459206894?lang=zh_cn&edition=full","pubTime":"2024-08-15 21:38","pubTimestamp":1723729097,"startTime":"0","endTime":"0","summary":"北京时间2024年08月15日21时38分，Fulcrum Therapeutics, Inc.股票出现异动，股价快速拉升5.27%。截至发稿，该股报9.50美元/股，成交量2.7079万股，换手率0.04%，振幅1.88%。Fulcrum Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.36%。其相关个股中，Cingulate Inc.、Nutriband Inc C/Wts 、Scisparc Ltd.涨幅较大，Cingulate Inc.、Scisparc Ltd.、Altamira Therapeutics Ltd.较为活跃，换手率分别为3278.23%、1587.18%、353.47%，振幅较大的相关个股有Seastar Medical Holding Corp C/Wts 28/10/2027 、Cingulate Inc.、Cingulate Inc C/Wts 10/12/2026 ，振幅分别为52.18%、45.53%、45.38%。Fulcrum Therapeutics, Inc.公司简介：Fulcrum Therapeutics Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240815213818a1d470f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240815213818a1d470f4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","FULC","LENZ"],"gpt_icon":0},{"id":"2459109596","title":"Fulcrum Therapeutics, Inc.盘中异动 早盘股价大跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2459109596","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459109596?lang=zh_cn&edition=full","pubTime":"2024-08-14 23:23","pubTimestamp":1723648987,"startTime":"0","endTime":"0","summary":"北京时间2024年08月14日23时23分，Fulcrum Therapeutics, Inc.股票出现异动，股价急速下跌5.03%。Fulcrum Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.32%。其相关个股中，Zura Bio Limited C/Wts 、Newamsterdam Pharma Co Nv C/Wts 、Revolution Medicines Inc C/Wts 17/12/2026 涨幅较大，Genprex, Inc.、Conduit Pharmaceuticals Inc.、Tc Biopharm  Plc较为活跃，换手率分别为87.41%、74.38%、66.10%，振幅较大的相关个股有Seastar Medical Holding Corp C/Wts 28/10/2027 、Genprex, Inc.、Tc Biopharm  Plc，振幅分别为60.83%、58.52%、49.86%。Fulcrum Therapeutics, Inc.公司简介：Fulcrum Therapeutics Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240814232307968263be&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240814232307968263be&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","FULC","BK4007","LENZ"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fulcrumtx.com","stockEarnings":[{"period":"1week","weight":-0.1676},{"period":"1month","weight":-0.1368},{"period":"3month","weight":-0.6783},{"period":"6month","weight":-0.607},{"period":"1year","weight":-0.2699},{"period":"ytd","weight":-0.5511}],"compareEarnings":[{"period":"1week","weight":-0.0177},{"period":"1month","weight":0.0061},{"period":"3month","weight":0.0527},{"period":"6month","weight":0.1101},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.2374}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Fulcrum Therapeutics, Inc.于2015年8月18日在特拉华州注册成立。他们是一家临床阶段的生物制药公司，致力于改善未满足医疗需求的遗传性疾病患者的生活，最初的重点是罕见疾病。他们开发了一种专有产品引擎，用于系统地识别和验证可能调节基因表达的细胞药物靶点，以治疗遗传定义疾病的已知根本原因。他们正在使用他们的产品引擎来识别可被小分子吸毒的目标，而不管基因错误表达的特定潜在机制。他们已经确定了治疗面肩肱型肌营养不良症（FSHD）和某些血红蛋白病（即镰状细胞病，SCD和b-地中海贫血）的根本原因的药物靶点。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.093943},{"month":2,"riseRate":0.6,"avgChangeRate":0.007062},{"month":3,"riseRate":0.2,"avgChangeRate":0.022339},{"month":4,"riseRate":0.2,"avgChangeRate":-0.189757},{"month":5,"riseRate":0.6,"avgChangeRate":0.060108},{"month":6,"riseRate":0.4,"avgChangeRate":-0.04331},{"month":7,"riseRate":0.6,"avgChangeRate":0.083911},{"month":8,"riseRate":0.5,"avgChangeRate":0.487567},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.171434},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.105879},{"month":11,"riseRate":0.666667,"avgChangeRate":0.215567},{"month":12,"riseRate":1,"avgChangeRate":0.212178}],"exchange":"NASDAQ","name":"Fulcrum Therapeutics","nameEN":"Fulcrum Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Fulcrum Therapeutics(FULC)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Fulcrum Therapeutics(FULC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Fulcrum Therapeutics,FULC,Fulcrum Therapeutics股票,Fulcrum Therapeutics股票老虎,Fulcrum Therapeutics股票老虎国际,Fulcrum Therapeutics行情,Fulcrum Therapeutics股票行情,Fulcrum Therapeutics股价,Fulcrum Therapeutics股市,Fulcrum Therapeutics股票价格,Fulcrum Therapeutics股票交易,Fulcrum Therapeutics股票购买,Fulcrum Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Fulcrum Therapeutics(FULC)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Fulcrum Therapeutics(FULC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}